English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

SB4 (Benepali ® ), the Etanercept biosimilar, is licenced in the UK for the same indications as the reference product, Enbrel ® . In 2016, the Rheumatology Department at Blackpool Teaching Hospitals switched the Etanercept patients, who gave consent, to SB4. A proportion of these patients switched back to Etanercept and therefore we aimed to investigate the reasons of SB4 withdrawal and compare our results with the current evidence.

mediterranean journal of rheumatology

Switching patients with inflammatory arthritis from Etanercept (Enbrel<sup>®</sup>) to the biosimilar drug, SB4 (Benepali<sup>®</sup>): A single-centre retrospective observational study in the UK and a review of the literature

Switching patients with inflammatory arthritis from Etanercept (Enbrel®) to the biosimilar drug, SB4 (Benepali®): A single-centre retrospective observational study in the UK and a review of the literature

Switching patients with inflammatory arthritis from Etanercept (Enbrel^®) to the biosimilar drug, SB4 (Benepali^®): A single-centre retrospective observational study in the UK and a review of the literature